Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Mar 19, 2023 5:10pm
165 Views
Post# 35347849

RE:RE:RE:RE:A friend is needed...

RE:RE:RE:RE:A friend is needed...Bioasis stated they had enough money for March. A payment to Lind is due on April 1 or almost immediately after that. I'm pointing out the types of events that Bioasis's financial needs could trigger in relation to the events happening at Midatech.

I suppose I could parse the words being used by both Bioasis and Midatech, and combine those parsings with Bioasis's needs and the timings and details related to the Midatech financing and general meeting and post it all here, but I don't owe that detail to anyone. Instead I posted what those things could mean.

I won't be convinced that Midatech (Biodexa) is out of the picture unless they're really out of the picture. And I am still suspicious about why Bioasis bought the Cresence EGF stuff. You'll find details of my suspicions buried in my many posts about it all.

Basically I think that EGF may be the consolation prize for either Bioasis or Biodexa, whichever one might lose xB3. I mean, come on! Denali has a market cap of $3.2 billion with an equivalent or inferior technology. There was a play put on to acquire Bioasis. The same players are putting Biodexa together after the first failure. 

Why? What are they intending to do with Biodexa? 

I believe that Bioasis has utterly failed, possibly due to incompetence, intention, or a combination of both. There were decisions made by Bioasis that are publicly documented and that support my concerns about that. 

This could be over in two weeks. If Biodexa issues the third loan tranche of its loan agreement with Bioasis, then it will take a bit longer for it to happen, but the outcome could be the same. 

jd
<< Previous
Bullboard Posts
Next >>